We are live on
!
Find out more
Handelsbanken Fonder Portfolio holdings
AUM
$35.1B
1-Year Est. Return
47.76%
This Fund
S&P 500
This Quarter
Est. Return
+2.36%
1 Year Est. Return
+47.76%
3 Year Est. Return
+137.96%
5 Year Est. Return
+170.36%
10 Year Est. Return
+934.7%
AUM
$26.2B
AUM Growth
+$914M
(+3.6%)
Cap. Flow
+$1.01B
Cap. Flow
% of AUM
3.87%
Top 10 Holdings %
Top 10 Hldgs %
32.55%
Holding
1,591
New
69
Increased
817
Reduced
431
Closed
49
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$107M |
| 2 |
EXL Service
EXLS
|
+$72M |
| 3 |
Apple
AAPL
|
+$64.3M |
| 4 |
Synopsys
SNPS
|
+$56.8M |
| 5 |
ServiceNow
NOW
|
+$54.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Halozyme
HALO
|
+$74.5M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$53.5M |
| 3 |
Edwards Lifesciences
EW
|
+$45M |
| 4 |
Abbott
ABT
|
+$40.3M |
| 5 |
Rockwell Automation
ROK
|
+$39.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.4% |
| 2 | Healthcare | 16.63% |
| 3 | Financials | 12.04% |
| 4 | Communication Services | 9.47% |
| 5 | Industrials | 8.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1376
Oscar Health
OSCR
$9.35B
| $401K | ﹤0.01% |
29,800
+17,800
| +148% | +$287K |
|
1377
Safety Insurance
SAFT
$1.52B
| $400K | ﹤0.01% |
4,858
+600
| +14% | +$49.7K |
|
1378
Trupanion
TRUP
$1.33B
| $400K | ﹤0.01% |
8,300
+2,400
| +41% | +$123K |
|
|
DAWN
1379
DELISTED
Day One Biopharmaceuticals
DAWN
| $399K | ﹤0.01% |
31,500
+4,500
| +17% | +$62.6K |
|
1380
Cohu
COHU
$2.79B
| $398K | ﹤0.01% |
14,900
+1,600
| +12% | +$41.9K |
|
|
RC
1381
Ready Capital
RC
$294M
| $396K | ﹤0.01% |
58,030
+10,600
| +22% | +$76.2K |
|
1382
Driven Brands
DRVN
$2.11B
| $392K | ﹤0.01% |
24,300
+4,800
| +25% | +$75.3K |
|
1383
Birkenstock
BIRK
$7.65B
| $391K | ﹤0.01% |
+6,900
| New | +$350K |
|
|
THS
1384
DELISTED
Treehouse Foods
THS
| $390K | ﹤0.01% |
11,109
-600
| -5% | -$21.9K |
|
|
AAT
1385
American Assets Trust
AAT
$1.41B
| $389K | ﹤0.01% |
14,802
+2,200
| +17% | +$60.1K |
|
1386
Trustmark
TRMK
$2.8B
| $388K | ﹤0.01% |
10,960
| – | – |
|
1387
WesBanco
WSBC
$4.09B
| $387K | ﹤0.01% |
11,900
+800
| +7% | +$26.5K |
|
1388
Surgery Partners
SGRY
$1.98B
| $383K | ﹤0.01% |
18,100
| – | – |
|
1389
CG Oncology
CGON
$6.68B
| $381K | ﹤0.01% |
+13,300
| New | +$455K |
|
1390
Stock Yards Bancorp
SYBT
$2.63B
| $380K | ﹤0.01% |
+5,300
| New | +$373K |
|
1391
National Beverage
FIZZ
$2.94B
| $379K | ﹤0.01% |
8,883
| – | – |
|
1392
Nelnet
NNI
$4.52B
| $379K | ﹤0.01% |
3,551
+1,200
| +51% | +$133K |
|
1393
Establishment Labs
ESTA
$2.29B
| $378K | ﹤0.01% |
8,200
+2,000
| +32% | +$87.2K |
|
1394
Banc of California
BANC
$3.13B
| $376K | ﹤0.01% |
24,316
+11,500
| +90% | +$181K |
|
1395
First Bancorp
FBNC
$2.73B
| $376K | ﹤0.01% |
8,544
| – | – |
|
|
CON
1396
Concentra Group Holdings
CON
$4.46B
| $375K | ﹤0.01% |
+18,972
| New | +$392K |
|
1397
Central Garden & Pet Co
CENT
$2.79B
| $373K | ﹤0.01% |
9,616
-700
| -7% | -$26.1K |
|
1398
Sally Beauty Holdings
SBH
$1.55B
| $373K | ﹤0.01% |
35,734
| – | – |
|
|
CIM
1399
Chimera Investment
CIM
$1B
| $371K | ﹤0.01% |
26,487
+9,000
| +51% | +$135K |
|
1400
Asana
ASAN
$2.07B
| $369K | ﹤0.01% |
18,200
+2,900
| +19% | +$45.9K |
|
Similar funds
VIA
GAM
Handelsbanken Fonder's Q4 2024 Portfolio in Review
As of Q4 2024, Handelsbanken Fonder held 1,591 positions worth $26.2B, up 3.6% from $25.3B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Handelsbanken Fonder deployed $1.01B of net new capital in Q4 2024, opening 69 new positions and adding to 817 existing holdings. Its largest new stake was GE Vernova: 105,537 shares worth $34.7M.
By sector, the portfolio is most concentrated in Technology at 37% of assets, up from 35% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Halozyme, an estimated $74.5M trimmed.
- Handelsbanken Fonder's largest Q4 2024 buy was GE Vernova: 105,537 shares worth $34.7M.
- Handelsbanken Fonder added most to Microsoft in Q4 2024, an estimated $107M increase.
- Handelsbanken Fonder's biggest Q4 2024 reduction was Halozyme, cutting an estimated $74.5M.
- Handelsbanken Fonder fully exited BeOne Medicines Ltd in Q4 2024, selling an estimated $5.92M.
- Handelsbanken Fonder's ten largest holdings make up 33% of its $26.2B portfolio in Q4 2024.
- Handelsbanken Fonder opened 69 new positions and closed 49 in Q4 2024.
- Handelsbanken Fonder's portfolio value rose 3.6% quarter-over-quarter to $26.2B.
Based on Handelsbanken Fonder's 13F filing for Q4 2024, filed 3 Feb 2025.